XCUR vs. THAR, CLVR, ALZN, GTBP, CYCC, PTPI, ENSC, SNGX, SEEL, and ZVSA
Should you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Tharimmune (THAR), Clever Leaves (CLVR), Alzamend Neuro (ALZN), GT Biopharma (GTBP), Cyclacel Pharmaceuticals (CYCC), Petros Pharmaceuticals (PTPI), Ensysce Biosciences (ENSC), Soligenix (SNGX), Seelos Therapeutics (SEEL), and ZyVersa Therapeutics (ZVSA). These companies are all part of the "pharmaceutical preparations" industry.
Tharimmune (NASDAQ:THAR) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
Tharimmune's return on equity of 27.15% beat Exicure's return on equity.
Exicure has higher revenue and earnings than Tharimmune.
Exicure received 9 more outperform votes than Tharimmune when rated by MarketBeat users.
Tharimmune has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Exicure has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
In the previous week, Exicure had 5 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Exicure and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.31 beat Exicure's score of 0.00 indicating that Exicure is being referred to more favorably in the news media.
1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by insiders. Comparatively, 8.4% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Exicure beats Tharimmune on 9 of the 10 factors compared between the two stocks.
Get Exicure News Delivered to You Automatically
Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
